Wu2017 - Murine Bevacizumab PK model Lab

{
  "io": {
    "inputs": [
      {
        "name": "dose_iv_parameter",
        "label": "Dose Iv Parameter",
        "units": "native source value",
        "default": 0.45,
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.dose_iv_parameter",
        "description": "Dose Iv Parameter. Sets bundled SBML parameter `dose_iv`."
      },
      {
        "name": "dose_sc_parameter",
        "label": "Dose Sc Parameter",
        "units": "native source value",
        "default": 0.45,
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.dose_sc_parameter",
        "description": "Dose Sc Parameter. Sets bundled SBML parameter `dose_sc`."
      }
    ],
    "outputs": [
      {
        "name": "cs_iv",
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.cs_iv"
      },
      {
        "name": "at_iv",
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.at_iv"
      },
      {
        "name": "cs_sc",
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.cs_sc"
      },
      {
        "name": "at_sc",
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.at_sc"
      },
      {
        "name": "cln_sc",
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.cln_sc"
      },
      {
        "name": "state",
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.state"
      },
      {
        "name": "summary",
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.summary"
      },
      {
        "name": "species_labels",
        "maps_to": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.species_labels"
      }
    ]
  },
  "title": "Wu2017 - Murine Bevacizumab PK model Lab",
  "models": [
    {
      "path": "models/core",
      "alias": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model"
    },
    {
      "path": "models/visualisation",
      "alias": "visualisation"
    }
  ],
  "wiring": [
    {
      "to": [
        "visualisation.immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model_state"
      ],
      "from": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.state"
    },
    {
      "to": [
        "visualisation.immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model_summary"
      ],
      "from": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.summary"
    },
    {
      "to": [
        "visualisation.immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model_species_labels"
      ],
      "from": "immunology_sbml_wu2017_murine_bevacizumab_pk_model_model2003030003_model.species_labels"
    }
  ],
  "package": "wu2017-murine-bevacizumab-pk-model",
  "runtime": {
    "duration": 10,
    "initial_inputs": {},
    "communication_step": 1
  },
  "version": "1.0.0",
  "description": "This is the first report evaluating the use of fluorescent imaging to determine the pharmacokinetics, lymphatic uptake, and bioavailability of a near-infrared dye-labeled antibody conjugate. It can be used to explore immune response dynamics and compare pathway-level behavior across conditions.",
  "schema_version": "2.0"
}